Zimmer Biomet (NYSE:ZBH) Raised to "Strong-Buy" at Rothschild Redb

Key Points

• Zimmer Biomet has been upgraded to a "strong-buy" rating by Rothschild Redb, highlighting increased investor confidence in the company's future performance.
• Despite this upgrade, other analysts have varied opinions, with Evercore ISI lowering its price objective from $102.00 to $96.00 and UBS Group maintaining a "sell" rating.
• The company's recent earnings report showed a revenue increase of 7.0% year-over-year, posting $2.08 billion and surpassing analyst expectations.

Zimmer Biomet (NYSE:ZBH - Get Free Report) was upgraded by equities research analysts at Rothschild Redb to a "strong-buy" rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

ZBH has been the topic of several other reports. Raymond James Financial boosted their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Evercore ISI cut their target price on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Royal Bank Of Canada lifted their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Finally, Rothschild & Co Redburn started coverage on Zimmer Biomet in a report on Thursday. They set a "buy" rating and a $130.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $113.16.

Zimmer Biomet Stock Down 0.2%

ZBH stock traded down $0.18 during midday trading on Thursday, reaching $100.03. 4,228,497 shares of the company were exchanged, compared to its average volume of 1,180,396. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet has a 1-year low of $89.22 and a 1-year high of $114.72. The stock's 50-day simple moving average is $100.06 and its 200 day simple moving average is $99.39. The company has a market cap of $19.82 billion, a price-to-earnings ratio of 24.34, a price-to-earnings-growth ratio of 2.30 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the firm posted $2.01 earnings per share. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current year.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.39% of the stock is owned by company insiders.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently modified their holdings of ZBH. OneDigital Investment Advisors LLC bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $269,000. Keybank National Association OH raised its position in Zimmer Biomet by 61.2% in the 1st quarter. Keybank National Association OH now owns 14,315 shares of the medical equipment provider's stock valued at $1,620,000 after purchasing an additional 5,434 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Zimmer Biomet by 26.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 316,308 shares of the medical equipment provider's stock valued at $35,800,000 after purchasing an additional 66,114 shares during the last quarter. Kingswood Wealth Advisors LLC raised its position in Zimmer Biomet by 20.0% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider's stock valued at $295,000 after purchasing an additional 435 shares during the last quarter. Finally, Polar Asset Management Partners Inc. bought a new stake in shares of Zimmer Biomet during the first quarter worth $6,462,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.